Jump to content

Ralpancizumab

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by AztecWarrior28 (talk | contribs) at 19:18, 8 February 2018 (add synonym). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Ralpancizumab
Monoclonal antibody
Type?
SourceHumanized (from mouse)
Targetneural apoptosis-regulated proteinase 1
Clinical data
Other namesRN317
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
Chemical and physical data
FormulaC6422H9922N1730O2012S54
Molar mass145.3 kg/mol g·mol−1

Ralpancizumab (RN317) (INN[1]) is a monoclonal antibody designed for the treatment of dyslipidemia.[2]

This drug was developed by Pfizer.

References

  1. ^ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Ralpancizumab, American Medical Association.
Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Ralpancizumab&oldid=824667000"